-
By Jenny Ivy |
May 22, 2012
A new in-depth survey on the state of pharmacy benefit management finds most sponsors are looking at a number of ways to control costs, but few have considered dropping coverage entirely.
-
By James E. Green |
February 24, 2012
A round-up of the week’s employee benefits news, reports and controversy from around the web
-
By Kathryn Mayer |
February 2, 2012
Folks in the health care industry say 2012 is a “tactical year” because of the overwhelming list of priorities and the need to carefully allocate resources with which to accomplish them.
-
By Sponsor: VSP |
January 12, 2012
Roundtable: How the Affordable Care Act Impacts Vision and Dental Plans
-
By Robert Oscar |
November 22, 2011
Today, smartphones are revolutionizing the way health care decisions are made and there is no better time than the present.
-
By Sponsor: Metlife |
September 9, 2011
The tenuous market conditions and slow economic recovery in which today’s brokers and consultants operate is only the beginning of their challenges. Healthcare reform presents another major change on the horizon.
-
By Kathryn Mayer |
June 20, 2011
After pressure from Democrats, consulting firm McKinsey released a statement Monday, along with the full questionnaire about its now-controversial survey predicting a significant drop of ESI coverage due to health reform.
-
By Sponsor: The American College |
May 20, 2011
In this informative podcast, faculty from The American College will talk about the state of healthcare reform as Washington increasingly focuses on deficit reduction.
-
By Dan Shellenbarger, Michael Main |
May 9, 2011
One year after the passage of healthcare reform—embodied in the blockbuster Patient Protection and Affordable Care Act (ACA)—it’s still difficult to see just what form it will take and, more important, what kind of impact it will have on the marketplace.
-
By Dan Shellenbarger, Michael Main |
May 1, 2011
One year after the passage of health care reform — embodied in the blockbuster Patient Protection and Affordable Care Act — it’s still difficult to see just what form it will take and, more importantly, what kind of impact it will have on the market.
